FDA approves Verona’s Ohtuvayre as COPD maintenance treatment in adults
27 Jun 2024
Preview
Source: PMLiVE
The US Food and Drug Administration (FDA) has approved Verona Pharma’s Ohtuvayre (ensifentrine) as a maintenance treatment for adults with chronic obstructive pulmonary disease (COPD).
More than 390 million people worldwide are living with COPD, a group of diseases that cause airflow blockage and breathing-related problems.
Despite available treatment options, COPD is the third leading cause of death globally, and approximately half of patients experience almost daily symptoms, including increased shortness of breath, frequent coughing and wheezing.
Ohtuvayre is a selective dual inhibitor of the enzymes phosphodiesterase 3 and phosphodiesterase 4 and is now the first inhaled therapy for COPD maintenance treatment that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule.
The therapy is delivered directly to the lungs through a standard jet nebuliser without the need for high inspiratory flow rates or complex hand-breath coordination.
Among the data supporting the FDA’s approval are results from the late-stage ENHANCE trials, in which Ohtuvayre was associated with clinical benefits as both a monotherapy and when used with other maintenance therapies.
Ohtuvayre met the primary endpoint in both ENHANCE-1 and ENHANCE-2, demonstrating statistically significant improvements in lung function across both primary and secondary endpoints.
Zaccardelli added that the company plans to launch Ohtuvayre in the third quarter of 2024, ensuring the therapy is “available to help the millions of patients who still experience daily COPD symptoms”.
Also commenting on the FDA’s decision, Michael Wells, associate professor in the division of pulmonary, allergy and critical care medicine at the University of Alabama Birmingham, said: “COPD has a significant impact on both mortality and morbidity in the US, and until today, innovation in inhaled treatment modalities has been limited to combinations of existing treatment classes for over two decades.
“Ohtuvayre… offers a needed, unique approach and is an important advance in the treatment of COPD.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.